Hydroxyapatite Injection Package

Calcium hydroxyapatite is a biocompatible material that mirrors the mineral component of bone and teeth. As an injectable aesthetic product it is formulated as microspheres (typically 25–45 micrometers) suspended in an aqueous carboxymethylcellulose (CMC) gel carrier. The product is CE-marked and FDA-approved for specific facial and hand indications; Radiesse is a widely recognized brand example (a registered trademark of Merz Pharmaceuticals), mentioned here only to orient readers and not as an endorsement.

Its clinical effect is dual. First, the CMC gel delivers immediate lift and contour at the moment of placement. Over the following weeks the gel is absorbed, while the CaHA microspheres remain in situ and act as a scaffold that fibroblasts respond to. Published dermatologic literature and American Academy of Dermatology (AAD) and American Society of Plastic Surgeons (ASPS) patient guidance describe this as a neocollagenesis response: new type-I and type-III collagen forms around the microspheres over approximately 3–6 months, supplying structural support that outlasts the initial gel-driven volume. The microspheres themselves gradually break down into calcium and phosphate ions that enter normal metabolic pathways.

Calcium hydroxyapatite is used where structural volumization and collagen stimulation are both desirable. At the category level this includes:

• Mid-face volume loss and cheek projection support
• Jawline contouring and mandibular-border definition
• Nasolabial-fold depth correction
• Marionette-line softening and pre-jowl support
• Neck and platysmal-band skin-quality treatment, and décolletage collagen stimulation
• Hand rejuvenation (age-related volume loss on the dorsum)

CaHA is not indicated for the glabella, periocular fine lines, or the lips. The product’s rheology (viscous, semi-rigid scaffold) and the vascular anatomy of the glabellar territory make these areas unsuitable; AAD and peer-reviewed injectable-safety literature list glabellar injection of CaHA as a recognized high-risk practice because of the embolic consequences if intravascular injection occurs in that region. Lip tissue is also outside the product’s indication — the mobile mucosa does not tolerate the microsphere scaffold well and nodule risk is unacceptably high.

CaHA is delivered as an in-office injection procedure — no operating theatre, no sedation, and no hospital admission are required. The treatment area is cleansed and photographed in standardized views, and topical anesthetic cream is applied; modern CaHA formulations can also be mixed with lidocaine immediately before injection to further reduce discomfort.

Product is placed via sharp needle or blunt-tipped cannula — the choice is driven by the anatomical area, vascular map, and target plane rather than by default technique:

• Mid-face structural lift — typically supraperiosteal (onto the bone) in the zygomatic and malar areas for projection and pillar support
• Jawline contour — typically deep subcutaneous along the mandibular border, with careful avoidance of the facial artery and marginal mandibular nerve
• Neck and décolletage — superficial subcutaneous delivery, often with a diluted or hyper-diluted preparation to favor collagen stimulation over focal volumization
• Hands — subdermal, in the intermetacarpal space, with manual tenting and distal milking for even distribution

Product is placed in incremental aliquots with intermittent massage, mirror re-assessment, and standardized post-treatment photography. A typical session takes approximately 15–30 minutes of chair time after topical anesthesia onset.

CaHA treatments are typically offered in several configurations depending on the anatomical goal and whether the session is combined with other modalities. Exact inclusions and pricing are defined by each provider and visible on the individual vendor pages.

Downtime after CaHA treatment is short. Typical aftercare guidance, consistent with AAD and ASPS patient information, is as follows:

• First 24–48 hours: avoid rubbing or massaging the treated area unless specifically instructed; avoid heat exposure (sauna, hot yoga, very hot showers); avoid intense exercise and alcohol
• Bruising and swelling: mild swelling and occasional pinpoint bruising are expected at injection sites, typically settling within 3–7 days
• Visible result: immediate volumetric change is visible from the end of the session (driven by the CMC gel carrier)
• Collagen-driven refinement: continued improvement from neocollagenesis develops progressively over the following 3–6 months
• Typical duration: 12–18 months depending on area, dose, metabolism, and whether touch-up sessions are performed

Makeup can generally be reapplied the following day over intact skin. Any concerning symptoms after treatment — severe or escalating pain, skin blanching or mottling, visual change, or spreading discoloration — should prompt immediate contact with the treating practice for urgent review.

CaHA has a well-characterized safety profile in the peer-reviewed dermatologic literature and in guidance from the American Academy of Dermatology (AAD) and the American Society of Plastic Surgeons (ASPS). Reported categories and indicative rates include:

• Bruising at injection sites: approximately 10–20% of treatments, typically resolving within 5–10 days
• Transient swelling and tenderness: expected for 1–3 days, longer in hand and neck territory
• Palpable or visible nodules: reported in under 5% of cases in published series; these can be early (technique-related, from superficial placement or bolus delivery) or delayed. KEY DIFFERENCE from hyaluronic acid fillers: CaHA nodules are NOT enzymatically reversible — there is no equivalent to hyaluronidase for CaHA. Nodules are managed conservatively and typically resolve over weeks to months, or are treated with intralesional steroid or 5-fluorouracil (5-FU) injection, manual massage, or — rarely — mechanical extraction. This non-reversibility is a defining clinical distinction between CaHA and HA filler and is a standard element of informed consent.
• Delayed inflammatory reactions: rare; may present weeks to months after treatment as localized swelling or redness, often triggered by intercurrent illness or dental procedures; managed medically
• Infection at the injection site: under 0.1%, as with other injectable fillers
• Vascular occlusion (inadvertent intravascular injection): rare but serious, estimated at under 1 per 1,000 to 1 per 10,000 treatments in published series across the filler class. Not reversible with hyaluronidase, unlike HA filler — this is the second major clinical distinction. Managed by emergency-response protocol (immediate cessation, warm compress, aspirin where appropriate, nitroglycerin paste, urgent ophthalmology review if visual symptoms, off-label attempts at dissolution are of limited efficacy for CaHA). Any provider offering CaHA should have a written vascular-event response protocol in place.
• Allergic or hypersensitivity reaction: very rare with CaHA

These risks are reviewed individually before consent. The absence of an enzymatic reversal agent is the central safety-conversation difference between CaHA and hyaluronic acid fillers and should be clearly understood by the patient before treatment proceeds.